Goldman Sachs Asset Management Raises $650M For Life Sciences I Fund, Targets Innovation
The Goldman Sachs Group Inc's (NYSE: GS) Goldman Sachs Asset Management recently
Goldman’s Symphony Of Ratings: Asset Management Moves For A Dynamic 2024
Goldman Sachs analyst Alexander Blostein revised the rating on several asset management stocks amid an updated outlook for American Capital Markets.
Chip Stocks At ‘Premium Valuations,’ But Bank Of America Remains Bullish On Semiconductors
Historically, large annual gains for the Philly Semi index have been followed by a further rally.
There’s Uncertainty Around Apple’s Patent Appeal For Watch, Masimo’s Royalty Exposure Is Priced In – Analyst Downgrades
Needham downgraded Masimo Corporation (NASDAQ: MASI), noting that though Apple Inc (NASDAQ: AAPL) royalties are not certain, but are mostly priced into MASI shares.
US Stocks Eye 3-Day Slump; Tech, Crypto Sell-Off Deepens, Oil, Dollar Rebound: What’s Driving Markets Wednesday?
The early 2024 sell-off is intensifying on Wall Street, with all major stock averages in the red on the second trading day of 2024.
Hyundai’s December Sales Dip 0.8%; Plans Strengthening Its Global EV Production Infrastructure
Hyundai Motor Co (OTC: HYMTF) disclosed a total global sales increase of 6.9% at
Verizon Vs. AT&T: Cash Flow Quality And Valuations Compared
Verizon Communications was recently upgraded by KeyBanc analyst Brandon Nispel, citing multiple tailwinds and attractive valuation.
Sky’s The Limit: RTX’s Raytheon JV Pockets Massive NATO Contract For Patriot Missiles
COMLOG, a joint venture between RTX Corp's (NYSE: RTX) Raytheon and MBDA Germany, won the first contract
Cigna’s Medicare Business Sale: Health Care Service Could Scoop The Business
Cigna Group (NYSE: CI) is reportedly in advanced negotiations to divest its Medicare Advantage division and is presently in discussions to sell it to Health Care Service Corp Inc (NASDAQ: HCSG) for around $3
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate